Vadadustat

Drug Profile

Vadadustat

Alternative Names: AKB-6548; MT 6548

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Antianaemics; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 06 Feb 2017 Phase-II clinical trials in Anaemia in Japan (PO) (Mitsubishi Tanabe Pharma pipeline, February 2017)
  • 20 Dec 2016 Vadadustat sub-licensed to Otsuka Pharmaceuticals in USA
  • 01 Dec 2016 Akebia Therapeutics initiates enrolment in a phase II trial for Anaemia in Japan (NCT03054350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top